BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.

Employees

104

Sector

Biotechnology & Medical Research

Calendar

2025-02-13 - Q4 2024 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
24-12-04	182.80 kr	+0.49%	187,401
24-12-03	181.90 kr	-6.09%	521,699
24-12-02	193.70 kr	+0.31%	164,413
24-11-29	193.10 kr	0.00%	335,042
24-11-28	193.10 kr	+2.99%	135,090

Delayed Quote Nasdaq Stockholm, December 03, 2024 at 12:00 pm EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart BIOARCTIC-AB

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

181.90SEK

Average target price

322.00SEK

Spread / Average Target

+77.02%

Consensus

Profit revisions

Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-12-04 pm EST			5-day change	1st Jan Change
182.80 ^SEK	+0.49%		-5.97%	-31.74%

Nov. 29	Di: These seven hard-to-get stocks to buy according to the experts	FW
Nov. 28	Stockholm Bullets - Lindab implements savings program, new share issue in Klarabo after acquisition	FW

Capitalization	16.08B 1.46B 1.39B 1.29B 1.15B 2.05B 124B 2.25B 5.96B 50.69B 5.48B 5.36B 218B	P/E ratio 2024 *	-72.3x	P/E ratio 2025 *	50.9x
Enterprise value	15.2B 1.38B 1.31B 1.22B 1.09B 1.94B 117B 2.13B 5.63B 47.92B 5.18B 5.07B 206B	EV / Sales 2024 *	60.5x	EV / Sales 2025 *	15.6x
Free-Float	44.08%	Yield 2024 *	-	Yield 2025 *	-

Di: These seven hard-to-get stocks to buy according to the experts	Nov. 29	FW
Stockholm Bullets - Lindab implements savings program, new share issue in Klarabo after acquisition	Nov. 28	FW
Bioarctics Leqembi launched in South Korea	Nov. 28	FW
Eisai Launches Leqembi in South Korea	Nov. 27	CI
Cassana Sciences collapsed after study disappointment in Alzheimer's	Nov. 26	FW
Goldman Sachs raises target price for Bioarctic to SEK 292 (286), reiterates Buy - BN	Nov. 25	FW
RBC raises target price for Bioarctic to SEK 340 (290), reiterates outperform - BN	Nov. 20	FW
Redeye raises motivated value for Bioarctic to SEK 310 (275)	Nov. 18	FW
DNB raises target price for Bioarctic to SEK 350 (270), reiterates Buy - BN	Nov. 18	FW
RX Securities raises target price for Bioarctic to SEK 330 (270), reiterates Buy - BN	Nov. 15	FW
BioArctic Partner Eisai Gains EMA Panel Backing for Alzheimer's Drug	Nov. 14	MT
Eisai Co., Ltd. and BioAge Labs, Inc. Announce CHMP Issues Positive Recommendation for Approval of Lecanemab in the EU	Nov. 14	CI
Cheerful on the Stockholm Stock Exchange, OMXS30 index up 0.8 percent	Nov. 14	FW

Di: These seven hard-to-get stocks to buy according to the experts	Nov. 29	FW
Goldman Sachs raises target price for Bioarctic to SEK 292 (286), reiterates Buy - BN	Nov. 25	FW
RBC raises target price for Bioarctic to SEK 340 (290), reiterates outperform - BN	Nov. 20	FW
Redeye raises motivated value for Bioarctic to SEK 310 (275)	Nov. 18	FW
DNB raises target price for Bioarctic to SEK 350 (270), reiterates Buy - BN	Nov. 18	FW

BioArctic AB Stock

Equities

BIOA B

SE0010323311

Biotechnology & Medical Research

Valuation: BioArctic AB

Chart: BioArctic AB

Latest news: BioArctic AB

Last Transcript: BioArctic AB

Analysts' recommendations: BioArctic AB

Press Releases: BioArctic AB

News in other languages: BioArctic AB

Quotes and Performance

Course Extremes

Managers and Directors: BioArctic AB

ETFs: BioArctic AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Number of shares and votes in BioArctic AB (publ) as of November 29, 2024	Nov. 29	AQ
Eisai Co., Ltd. - LEQEMBI for the Treatment of Alzheimer's disease Launched in South Korea	Nov. 28	AQ
Leqembi[®] launched in South Korea	Nov. 27	AQ
BioArctic Q3 2024 - Positive CHMP opinion a relief for the share	Nov. 18	AQ
CHMP issues positive recommendation for approval of lecanemab in the EU	Nov. 14	AQ

Les actions en mouvement : Brunello Cucinelli, Kalray, Thermador et d'autres	Jul. 12
En Direct des Marchés : Crédit Agricole, Stellantis, Ipsen, Eurofins Scientific, Novo Nordisk...	Jul. 11
Une baisse de l'inflation s'il-vous-plaît !	Jul. 11
Le jour de la marmotte	Jun. 10
En Direct des Marchés : Stellantis, Crédit Agricole, LVMH, Volvo, Microsoft, Apple, Southwest Airlines...	Jun. 10

1 day	+0.82%
1 week	-6.43%
Current month	-5.80%
1 month	+26.85%
3 months	+10.11%
6 months	-26.48%
Current year	-32.08%

Director	Title	Age	Since
Gunilla Christina Osswald CEO	Chief Executive Officer	63	2012-12-31
Anders Martin-Löf DFI	Director of Finance/CFO	53	2023-05-31
Johanna Fälting CTO	Chief Tech/Sci/R&D Officer	52	2011-12-31

Manager	Title	Age	Since
Pär Lars Gellerfors BRD	Director/Board Member	77	2003-01-23
Lars Gunnar Lannfelt CHM	Chairman	75	2003-01-27
Eugen Steiner CHM	Chairman	70	2023-05-31

Name	Weight	AuM	1st Jan change	Investor Rating
FIRST TRUST IPOX EUROPE EQUITY OPPORTUNITIES ETF - DISTRIBUTING - USD	1.25%	4 M€	+19.51%
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD	0.19%	2 M€	-.--%
BMO MSCI INNOVATION INDEX ETF - CAD	0.07%	7 M€	-.--%	-
SIMPLIFY DEVELOPED EX-US PLUS DOWNSIDE CONVEXITY ETF - USD	0.01%	10 M€	-3.35%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
BIOARCTIC AB	+1.02%	-6.43%	-21.53%	+60.97%	1.46B
LONZA GROUP AG	-0.06%	-1.13%	+56.81%	-26.92%	42.79B
IQVIA HOLDINGS INC.	-0.60%	-0.32%	-7.53%	-23.35%	36.41B
CELLTRION, INC.	+1.25%	+6.44%	+14.59%	-5.81%	27.1B
ICON PUBLIC LIMITED COMPANY	-0.27%	+0.40%	-20.92%	-21.93%	17.58B
MODERNA, INC.	-3.80%	+1.26%	-46.66%	-86.12%	16.39B
UNITED THERAPEUTICS CORPORATION	-0.36%	-2.18%	+53.20%	+98.28%	16.46B
BIO-TECHNE CORPORATION	-1.28%	+0.24%	+16.23%	-34.19%	11.92B
MEDPACE HOLDINGS, INC.	-0.90%	+1.21%	+23.19%	+64.58%	10.52B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.97%	+0.78%	-1.18%	-44.23%	10.19B
Average	-0.05%	-0.18%	+6.62%	-1.87%	19.08B
Weighted average by Cap.	+0.08%	+0.40%	+14.10%	-12.72%

	2024 *	2025 *
Net sales	251M 22.81M 21.7M 20.21M 18.01M 32.09M 1.93B 35.22M 93.17M 792M 85.7M 83.78M 3.41B	973M 88.3M 84M 78.24M 69.74M 124M 7.48B 136M 361M 3.07B 332M 324M 13.2B
Net income	-223M -20.22M -19.24M -17.92M -15.97M -28.45M -1.71B -31.23M -82.61M -703M -75.99M -74.29M -3.02B	288M 26.16M 24.88M 23.18M 20.66M 36.8M 2.22B 40.4M 107M 909M 98.29M 96.09M 3.91B
Net Debt	-878M -79.67M -75.79M -70.6M -62.93M -112M -6.75B -123M -325M -2.77B -299M -293M -11.91B	-943M -85.6M -81.44M -75.86M -67.61M -120M -7.25B -132M -350M -2.97B -322M -314M -12.8B